Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
about
Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptorsCrizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.Zykadia (Ceritinib) Approved for Patients with Crizotinib-Resistant ALK -Positive Non-Small-Cell Lung Cancer.Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches.Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.Standardized Uptake Values Derived from 18F-FDG PET May Predict Lung Cancer Microvessel Density and Expression of KI 67, VEGF, and HIF-1α but Not Expression of Cyclin D1, PCNA, EGFR, PD L1, and p53.
P2860
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
@en
type
label
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
@en
prefLabel
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
@en
P2860
P356
P1476
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
@en
P2093
Victoria M Villaflor
P2860
P356
10.4103/1477-3163.109253
P407
P50
P577
2013-03-18T00:00:00Z